N-[(piperazinyl)hetaryl]arylsulfonamide compounds

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S253010, C544S295000, C544S360000

Reexamination Certificate

active

07320979

ABSTRACT:
The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula Iin whichQ is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rawhich is/are selected, independently of each other, from halogen, CN, NO2, CO2R4, COR5, C1-C4-alkyl and C1-C4-haloalkyl;Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rb, which is/are selected from halogen, NO2, CN, CO2R4, COR5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl and C1-C4-haloalkyl, with it also being possible for two radicals Rbwhich are bonded to adjacent C atoms of Ar to be together C3-C4-alkylene;R1is hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C4-alkenyl or C3-C4-alkynyl;with the radicals n, R1, R2, R3, R4and R5having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims1to10and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D3receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.

REFERENCES:
patent: 4577020 (1986-03-01), Gall
patent: 5958923 (1999-09-01), Hellendahl et al.
patent: 6090807 (2000-07-01), Hellendahl et al.
patent: 6172227 (2001-01-01), Xiang et al.
patent: 6342604 (2002-01-01), Hellendahl et al.
patent: 6380206 (2002-04-01), Pamukcu et al.
patent: 6472392 (2002-10-01), Starck et al.
patent: WO 03/002543 (2003-01-01), None
patent: WO 2004/058265 (2004-07-01), None
Jones et al. Chemical Abstracts, vol. 141, No. 123654 (Abstract for WO 2004/058265, Jul. 15, 2004) (2004).
Database Chemcats, Chemical Abstracts Service, Columbus, Ohio, US; XP002294060.
Willecomme, B.: Recherches dans la série de la pipérizine; Annales de Chimie, vol. 4, No. 6, 1969, pp. 405-428, XP009035691.
Bromidge et al; “5-Chloro-N-(4-methoxy-3-piperazine-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist”; Journal of Medicinal Chemistry, American Chemican Society, Washington, D.C. US, vol. 42, No. 2, Jan. 28, 1999, pp. 202-205, XP002109186; ISSN: 0022-2623.
Bromidge, S.M. et al; “Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT6 receptor”; Bioorg. med. chem. Lett., vol. 11, 2001, pp. 2843-2846, XP002294076.
J.C. Schwartz, et al., The Dopamine D3Receptor as a Target for Antiphyschotics; Novel Antipsychotic Drugs, Raven Press, Ltd., 1992, pp. 135-144; France.
M. Dooley, et al., Pramipexole—A Review of Its use in the Management of Early and Advanced Parkinson's Disease; Drugs & Aging, 1998, vol. 12, pp. 495-514, New Zealand.
J.N. Joyce, Dopamine D3receptor as a therapeutic target for antiphyschotic and antiparkinsonian drugs; Pharmacology & Therapeutics, 2001, vol. 90, pp. 231-259, USA.
P. Solokoff, et al, Localization and Function of the D3 Dopamine Receptor; Arzneim-Forsch./Drug Res. vol. 42(1), 12992, pp. 224-230, France.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

N-[(piperazinyl)hetaryl]arylsulfonamide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-[(piperazinyl)hetaryl]arylsulfonamide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-[(piperazinyl)hetaryl]arylsulfonamide compounds will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2799620

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.